NAV

Virus Specific T-Cell

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Virus Specific T-Cell
Accession Number
DB15735
Description

Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Autologous cell transplant / Other cell transplant therapies
Synonyms
  • HLA-matched Virus Specific T Cells
  • Partially HLA-matched Virus Specific T Cell
  • Viral Specific T-lymphocytes
  • VST
External IDs
  • Virus Specific T-Cell

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Houghtelin A, Bollard CM: Virus-Specific T Cells for the Immunocompromised Patient. Front Immunol. 2017 Oct 11;8:1272. doi: 10.3389/fimmu.2017.01272. eCollection 2017. [PubMed:29075259]
  2. Barrett AJ, Prockop S, Bollard CM: Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 Jan;24(1):13-18. doi: 10.1016/j.bbmt.2017.10.004. Epub 2017 Oct 12. [PubMed:29032062]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Viral Infections1
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID 19 / SARS-CoV 2 / Viral Infections1
1, 2Active Not RecruitingTreatmentAdenovirus Infections / Cytomegalovirus (CMV) Infection / Epstein-Barr Virus Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 14:16 / Updated on August 13, 2020 01:02